anti-IL-13R CAR T-cell therapy (TNK Therapeutics)

N/A

Report date: 2025/03/14 16:48:49

Base Information

Drug Nameanti-IL-13R CAR T-cell therapy (TNK Therapeutics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionInterleukin 13 receptor modulators

TargetsInterleukin 13 receptor

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTnk Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesTnk Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A